Private plan not entered. Private-plan coverage, and how it coordinates with public programs, is not determined here; the Ontario public-program lines on this page remain conditional on the entered details and the program rules.
Cefprozil
Form:
17 of 17 products shown
11 general benefit · 6 not a benefit
Auro-Cefprozil · DIN 02347261 · 125 mg/5 mL · Oral suspension-75mL Pk
General benefitMarketed · checked October 5, 2026
StatusGeneral benefit
Write on scriptno code needed
Patient paysODB senior: $100/program-year deductible
• Then up to $6.11 per prescription
Or, if enrolled in the Seniors Co-Payment Program (income-tested; individual net income below $25,480 for Aug 2026–Jul 2027): no deductible, up to $2 per prescription
1 brand, same coverage
Auro-Cefprozil · DIN 02347261
Manufacturer: Auro Pharma Inc.; listing date 2012-11-27
Health Canada: Marketed since 2024-03-01 · brand AURO-CEFPROZIL · ATC J01DC10 CEFPROZIL · form Powder for suspension · route Oral · ingredients CEFPROZIL (CEFPROZIL MONOHYDRATE) 125 MG/5ML · company Auro pharma inc · schedule Prescription
Auro-Cefprozil: Formulary list price $7.28 per unit (the source does not state the unit; exact figure $7.2750). What the ministry pays, not the patient.
DIN 02347261: Auro-Cefprozil
Raw flags: sec3=Y
Item: 081228083; group id 40; item number 0083; lccId None; manufacturer id AUR
Source form: Oral Susp-75mL Pk; strength: 125mg/5mL
Recorded listing: General benefit
Source prices (unrounded): $7.2750; ministry $7.2750
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02347261
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=83267Interchangeable products
Cefzil · DIN 02163675 · not recorded
Ran-Cefprozil · DIN 02329204 · $7.2750
Shortage status: resolved shortage (ended December 16, 2024); reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02347261
Shortage record checked October 6, 2026
Ran-Cefprozil · DIN 02329204 · 125 mg/5 mL · Oral suspension-75mL Pk
General benefitMarketed · checked October 5, 2026
StatusGeneral benefit
Write on scriptno code needed
Patient paysODB senior: $100/program-year deductible
• Then up to $6.11 per prescription
Or, if enrolled in the Seniors Co-Payment Program (income-tested; individual net income below $25,480 for Aug 2026–Jul 2027): no deductible, up to $2 per prescription
1 brand, same coverage
Ran-Cefprozil · DIN 02329204
Manufacturer: Ranbaxy Pharmaceuticals Canada Inc.; listing date 2010-06-14
Health Canada: Marketed since 2025-10-31 · brand SPC-CEFPROZIL · ATC J01DC10 CEFPROZIL · form Powder for suspension · route Oral · ingredients CEFPROZIL (CEFPROZIL MONOHYDRATE) 125 MG/5ML · company Sun pharma canada inc · schedule Prescription
Ran-Cefprozil: Formulary list price $7.28 per unit (the source does not state the unit; exact figure $7.2750). What the ministry pays, not the patient.
DIN 02329204: Ran-Cefprozil
Raw flags: sec3=Y
Item: 081228083; group id 40; item number 0083; lccId None; manufacturer id RAN
Source form: Oral Susp-75mL Pk; strength: 125mg/5mL
Recorded listing: General benefit
Source prices (unrounded): $7.2750; ministry $7.2750
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02329204
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=81489Interchangeable products
Auro-Cefprozil · DIN 02347261 · $7.2750
Cefzil · DIN 02163675 · not recorded
Shortage status: resolved shortage (ended August 21, 2023); reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02329204
Shortage record checked October 6, 2026
Auro-Cefprozil · DIN 02347288 · 250 mg/5 mL · Oral suspension-75mL Pk
General benefitMarketed · checked October 5, 2026
StatusGeneral benefit
Write on scriptno code needed
Patient paysODB senior: $100/program-year deductible
• Then up to $6.11 per prescription
Or, if enrolled in the Seniors Co-Payment Program (income-tested; individual net income below $25,480 for Aug 2026–Jul 2027): no deductible, up to $2 per prescription
1 brand, same coverage
Auro-Cefprozil · DIN 02347288
Manufacturer: Auro Pharma Inc.; listing date 2012-11-27
Health Canada: Marketed since 2024-03-01 · brand AURO-CEFPROZIL · ATC J01DC10 CEFPROZIL · form Powder for suspension · route Oral · ingredients CEFPROZIL (CEFPROZIL MONOHYDRATE) 250 MG/5ML · company Auro pharma inc · schedule Prescription
Auro-Cefprozil: Formulary list price $14.54 per unit (the source does not state the unit; exact figure $14.5350). What the ministry pays, not the patient.
DIN 02347288: Auro-Cefprozil
Raw flags: sec3=Y
Item: 081228084; group id 40; item number 0084; lccId None; manufacturer id AUR
Source form: Oral Susp-75mL Pk; strength: 250mg/5mL
Recorded listing: General benefit
Source prices (unrounded): $14.5350; ministry $14.5350
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02347288
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=83268Interchangeable products
Cefzil · DIN 02163683 · not recorded
Ran-Cefprozil · DIN 02293579 · $14.5350
Shortage status: resolved shortage (ended December 16, 2024); reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02347288
Shortage record checked October 6, 2026
Ran-Cefprozil · DIN 02293579 · 250 mg/5 mL · Oral suspension-75mL Pk
General benefitMarketed · checked October 5, 2026
StatusGeneral benefit
Write on scriptno code needed
Patient paysODB senior: $100/program-year deductible
• Then up to $6.11 per prescription
Or, if enrolled in the Seniors Co-Payment Program (income-tested; individual net income below $25,480 for Aug 2026–Jul 2027): no deductible, up to $2 per prescription
1 brand, same coverage
Ran-Cefprozil · DIN 02293579
Manufacturer: Ranbaxy Pharmaceuticals Canada Inc.; listing date 2007-09-04
Health Canada: Marketed since 2025-10-31 · brand SPC-CEFPROZIL · ATC J01DC10 CEFPROZIL · form Powder for suspension · route Oral · ingredients CEFPROZIL (CEFPROZIL MONOHYDRATE) 250 MG/5ML · company Sun pharma canada inc · schedule Prescription
Ran-Cefprozil: Formulary list price $14.54 per unit (the source does not state the unit; exact figure $14.5350). What the ministry pays, not the patient.
DIN 02293579: Ran-Cefprozil
Raw flags: sec3=Y
Item: 081228084; group id 40; item number 0084; lccId None; manufacturer id RAN
Source form: Oral Susp-75mL Pk; strength: 250mg/5mL
Recorded listing: General benefit
Source prices (unrounded): $14.5350; ministry $14.5350
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02293579
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=77893Interchangeable products
Auro-Cefprozil · DIN 02347288 · $14.5350
Cefzil · DIN 02163683 · not recorded
Shortage status: resolved shortage (ended October 16, 2023); reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02293579
Shortage record checked October 6, 2026
Ran-Cefprozil · DIN 02293528 · 250 mg · tablet
General benefitMarketed · checked October 5, 2026
StatusGeneral benefit
Write on scriptno code needed
Patient paysODB senior: $100/program-year deductible
• Then up to $6.11 per prescription
Or, if enrolled in the Seniors Co-Payment Program (income-tested; individual net income below $25,480 for Aug 2026–Jul 2027): no deductible, up to $2 per prescription
1 brand, same coverage
Ran-Cefprozil · DIN 02293528
Manufacturer: Ranbaxy Pharmaceuticals Canada Inc.; listing date 2007-06-06
Health Canada: Marketed since 2025-06-18 · brand SPC-CEFPROZIL · ATC J01DC10 CEFPROZIL · form Tablet · route Oral · ingredients CEFPROZIL (CEFPROZIL MONOHYDRATE) 250 MG · company Sun pharma canada inc · schedule Prescription
Ran-Cefprozil: Formulary list price $1.74 per unit (the source does not state the unit; exact figure $1.7374). What the ministry pays, not the patient.
DIN 02293528: Ran-Cefprozil
Raw flags: sec3=Y
Item: 081228085; group id 40; item number 0085; lccId None; manufacturer id RAN
Source form: Tab; strength: 250mg
Recorded listing: General benefit
Source prices (unrounded): $1.7374; ministry $1.7374
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02293528
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=77887Interchangeable products
Cefzil · DIN 02163659 · not recorded
Shortage status: resolved shortage (ended December 21, 2022); reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02293528
Shortage record checked October 6, 2026
Auro-Cefprozil · DIN 02347253 · 500 mg · tablet
General benefitMarketed · checked October 5, 2026
StatusGeneral benefit
Write on scriptno code needed
Patient paysODB senior: $100/program-year deductible
• Then up to $6.11 per prescription
Or, if enrolled in the Seniors Co-Payment Program (income-tested; individual net income below $25,480 for Aug 2026–Jul 2027): no deductible, up to $2 per prescription
1 brand, same coverage
Auro-Cefprozil · DIN 02347253
Manufacturer: Auro Pharma Inc.; listing date 2012-04-24
Health Canada: Marketed since 2019-01-23 · brand AURO-CEFPROZIL · ATC J01DC10 CEFPROZIL · form Tablet · route Oral · ingredients CEFPROZIL 500 MG · company Auro pharma inc · schedule Prescription
Auro-Cefprozil: Formulary list price $2.00 per unit (the source does not state the unit; exact figure $2.0038). What the ministry pays, not the patient.
DIN 02347253: Auro-Cefprozil
Raw flags: sec3=Y
Item: 081228086; group id 40; item number 0086; lccId None; manufacturer id AUR
Source form: Tab; strength: 500mg
Recorded listing: General benefit
Source prices (unrounded): $2.0038; ministry $2.0038
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02347253
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=83266Interchangeable products
Cefzil · DIN 02163667 · not recorded
Ran-Cefprozil · DIN 02293536 · $2.0038
Shortage status: resolved shortage (ended March 6, 2025); reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02347253
Shortage record checked October 6, 2026
Ran-Cefprozil · DIN 02293536 · 500 mg · tablet
General benefitMarketed · checked October 5, 2026
StatusGeneral benefit
Write on scriptno code needed
Patient paysODB senior: $100/program-year deductible
• Then up to $6.11 per prescription
Or, if enrolled in the Seniors Co-Payment Program (income-tested; individual net income below $25,480 for Aug 2026–Jul 2027): no deductible, up to $2 per prescription
1 brand, same coverage
Ran-Cefprozil · DIN 02293536
Manufacturer: Ranbaxy Pharmaceuticals Canada Inc.; listing date 2007-06-06
Health Canada: Marketed since 2025-06-18 · brand SPC-CEFPROZIL · ATC J01DC10 CEFPROZIL · form Tablet · route Oral · ingredients CEFPROZIL (CEFPROZIL MONOHYDRATE) 500 MG · company Sun pharma canada inc · schedule Prescription
Ran-Cefprozil: Formulary list price $2.00 per unit (the source does not state the unit; exact figure $2.0038). What the ministry pays, not the patient.
DIN 02293536: Ran-Cefprozil
Raw flags: sec3=Y
Item: 081228086; group id 40; item number 0086; lccId None; manufacturer id RAN
Source form: Tab; strength: 500mg
Recorded listing: General benefit
Source prices (unrounded): $2.0038; ministry $2.0038
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02293536
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=77888Interchangeable products
Auro-Cefprozil · DIN 02347253 · $2.0038
Cefzil · DIN 02163667 · not recorded
Shortage status: no shortage or discontinuation reported (checked October 6, 2026); reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02293536
General benefitOntario PIN; no Health Canada record under this code
StatusGeneral benefit
Write on scriptno code needed
Patient paysODB senior: $100/program-year deductible
• Then up to $6.11 per prescription
Or, if enrolled in the Seniors Co-Payment Program (income-tested; individual net income below $25,480 for Aug 2026–Jul 2027): no deductible, up to $2 per prescription
No Health Canada record under this code: Ontario lists it under a product identification number (PIN), not a DIN.
Look up the brand's own DIN on Health Canada: https://health-products.canada.ca/dpd-bdpp/index-eng.jsp
Auro-Cefprozil · DIN 09858332
Manufacturer: Auro Pharma Inc.; listing date 2024-04-30
No Health Canada record under this code: Ontario lists it under a product identification number (PIN), not a DIN.
Look up the brand's own DIN on Health Canada: https://health-products.canada.ca/dpd-bdpp/index-eng.jsp
Auro-Cefprozil: Formulary list price $9.70 per unit (the source does not state the unit; exact figure $9.7000). What the ministry pays, not the patient.
DIN 09858332: Auro-Cefprozil
Raw flags: sec3=Y
Item: 081228123; group id 40; item number 0081; lccId None; manufacturer id AUR
Source form: Oral Susp-100mL Pk; strength: 125mg/5mL
Recorded listing: General benefit
Source prices (unrounded): $9.7000; ministry $9.7000
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=09858332
Look up the brand's own DIN on Health Canada: https://health-products.canada.ca/dpd-bdpp/index-eng.jspInterchangeable products
Cefzil · DIN 09857358 · not recorded
Ran-Cefprozil · DIN 09857356 · $9.7000
Shortage status: no shortage or discontinuation reported (checked October 6, 2026); reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=09858332
General benefitOntario PIN; no Health Canada record under this code
StatusGeneral benefit
Write on scriptno code needed
Patient paysODB senior: $100/program-year deductible
• Then up to $6.11 per prescription
Or, if enrolled in the Seniors Co-Payment Program (income-tested; individual net income below $25,480 for Aug 2026–Jul 2027): no deductible, up to $2 per prescription
No Health Canada record under this code: Ontario lists it under a product identification number (PIN), not a DIN.
Look up the brand's own DIN on Health Canada: https://health-products.canada.ca/dpd-bdpp/index-eng.jsp
Ran-Cefprozil · DIN 09857356
Manufacturer: Ranbaxy Pharmaceuticals Canada Inc.; listing date 2010-06-14
No Health Canada record under this code: Ontario lists it under a product identification number (PIN), not a DIN.
Look up the brand's own DIN on Health Canada: https://health-products.canada.ca/dpd-bdpp/index-eng.jsp
Ran-Cefprozil: Formulary list price $9.70 per unit (the source does not state the unit; exact figure $9.7000). What the ministry pays, not the patient.
DIN 09857356: Ran-Cefprozil
Raw flags: sec3=Y
Item: 081228123; group id 40; item number 0081; lccId None; manufacturer id RAN
Source form: Oral Susp-100mL Pk; strength: 125mg/5mL
Recorded listing: General benefit
Source prices (unrounded): $9.7000; ministry $9.7000
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=09857356
Look up the brand's own DIN on Health Canada: https://health-products.canada.ca/dpd-bdpp/index-eng.jspInterchangeable products
Auro-Cefprozil · DIN 09858332 · $9.7000
Cefzil · DIN 09857358 · not recorded
Shortage status: no shortage or discontinuation reported (checked October 6, 2026); reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=09857356
General benefitOntario PIN; no Health Canada record under this code
StatusGeneral benefit
Write on scriptno code needed
Patient paysODB senior: $100/program-year deductible
• Then up to $6.11 per prescription
Or, if enrolled in the Seniors Co-Payment Program (income-tested; individual net income below $25,480 for Aug 2026–Jul 2027): no deductible, up to $2 per prescription
No Health Canada record under this code: Ontario lists it under a product identification number (PIN), not a DIN.
Look up the brand's own DIN on Health Canada: https://health-products.canada.ca/dpd-bdpp/index-eng.jsp
Auro-Cefprozil · DIN 09858333
Manufacturer: Auro Pharma Inc.; listing date 2024-04-30
No Health Canada record under this code: Ontario lists it under a product identification number (PIN), not a DIN.
Look up the brand's own DIN on Health Canada: https://health-products.canada.ca/dpd-bdpp/index-eng.jsp
Auro-Cefprozil: Formulary list price $19.38 per unit (the source does not state the unit; exact figure $19.3800). What the ministry pays, not the patient.
DIN 09858333: Auro-Cefprozil
Raw flags: sec3=Y
Item: 081228124; group id 40; item number 0082; lccId None; manufacturer id AUR
Source form: Oral Susp-100mL Pk; strength: 250mg/5mL
Recorded listing: General benefit
Source prices (unrounded): $19.3800; ministry $19.3800
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=09858333
Look up the brand's own DIN on Health Canada: https://health-products.canada.ca/dpd-bdpp/index-eng.jspInterchangeable products
Cefzil · DIN 09857359 · not recorded
Ran-Cefprozil · DIN 09857365 · $19.3800
Shortage status: no shortage or discontinuation reported (checked October 6, 2026); reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=09858333
General benefitOntario PIN; no Health Canada record under this code
StatusGeneral benefit
Write on scriptno code needed
Patient paysODB senior: $100/program-year deductible
• Then up to $6.11 per prescription
Or, if enrolled in the Seniors Co-Payment Program (income-tested; individual net income below $25,480 for Aug 2026–Jul 2027): no deductible, up to $2 per prescription
No Health Canada record under this code: Ontario lists it under a product identification number (PIN), not a DIN.
Look up the brand's own DIN on Health Canada: https://health-products.canada.ca/dpd-bdpp/index-eng.jsp
Ran-Cefprozil · DIN 09857365
Manufacturer: Ranbaxy Pharmaceuticals Canada Inc.; listing date 2010-06-14
No Health Canada record under this code: Ontario lists it under a product identification number (PIN), not a DIN.
Look up the brand's own DIN on Health Canada: https://health-products.canada.ca/dpd-bdpp/index-eng.jsp
Ran-Cefprozil: Formulary list price $19.38 per unit (the source does not state the unit; exact figure $19.3800). What the ministry pays, not the patient.
DIN 09857365: Ran-Cefprozil
Raw flags: sec3=Y
Item: 081228124; group id 40; item number 0082; lccId None; manufacturer id RAN
Source form: Oral Susp-100mL Pk; strength: 250mg/5mL
Recorded listing: General benefit
Source prices (unrounded): $19.3800; ministry $19.3800
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=09857365
Look up the brand's own DIN on Health Canada: https://health-products.canada.ca/dpd-bdpp/index-eng.jspInterchangeable products
Auro-Cefprozil · DIN 09858333 · $19.3800
Cefzil · DIN 09857359 · not recorded
Shortage status: no shortage or discontinuation reported (checked October 6, 2026); reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=09857365
Listed, not a benefitOntario PIN; no Health Canada record under this code
StatusListed, not a benefit
Write on scriptnot a benefit; no Exceptional Access criteria on record (an EAP request with clinical rationale is still possible); see alternatives
Patient paysNot paid by ODB 65 and over; see alternatives
No Health Canada record under this code: Ontario lists it under a product identification number (PIN), not a DIN.
Look up the brand's own DIN on Health Canada: https://health-products.canada.ca/dpd-bdpp/index-eng.jsp
Cefzil · DIN 09857358
Manufacturer: Bristol Myers Squibb Canada Inc; listing date 2010-06-14
No Health Canada record under this code: Ontario lists it under a product identification number (PIN), not a DIN.
Look up the brand's own DIN on Health Canada: https://health-products.canada.ca/dpd-bdpp/index-eng.jsp
DIN 09857358: Cefzil
Raw flags: notABenefit=Y, sec3=Y
Item: 081228123; group id 40; item number 0081; lccId None; manufacturer id BQU
Source form: Oral Susp-100mL Pk; strength: 125mg/5mL
Recorded listing: Listed, not a benefit; ODB pays only for the benefit products in this interchangeable category
Source prices (unrounded): not recorded; ministry not recorded
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=09857358
Look up the brand's own DIN on Health Canada: https://health-products.canada.ca/dpd-bdpp/index-eng.jspInterchangeable products
Auro-Cefprozil · DIN 09858332 · $9.7000
Ran-Cefprozil · DIN 09857356 · $9.7000
Shortage status: no shortage or discontinuation reported (checked October 6, 2026); reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=09857358
Listed, not a benefitOntario PIN; no Health Canada record under this code
StatusListed, not a benefit
Write on scriptnot a benefit; no Exceptional Access criteria on record (an EAP request with clinical rationale is still possible); see alternatives
Patient paysNot paid by ODB 65 and over; see alternatives
No Health Canada record under this code: Ontario lists it under a product identification number (PIN), not a DIN.
Look up the brand's own DIN on Health Canada: https://health-products.canada.ca/dpd-bdpp/index-eng.jsp
Cefzil · DIN 09857359
Manufacturer: Bristol Myers Squibb Canada Inc; listing date 2010-06-14
No Health Canada record under this code: Ontario lists it under a product identification number (PIN), not a DIN.
Look up the brand's own DIN on Health Canada: https://health-products.canada.ca/dpd-bdpp/index-eng.jsp
DIN 09857359: Cefzil
Raw flags: notABenefit=Y, sec3=Y
Item: 081228124; group id 40; item number 0082; lccId None; manufacturer id BQU
Source form: Oral Susp-100mL Pk; strength: 250mg/5mL
Recorded listing: Listed, not a benefit; ODB pays only for the benefit products in this interchangeable category
Source prices (unrounded): not recorded; ministry not recorded
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=09857359
Look up the brand's own DIN on Health Canada: https://health-products.canada.ca/dpd-bdpp/index-eng.jspInterchangeable products
Auro-Cefprozil · DIN 09858333 · $19.3800
Ran-Cefprozil · DIN 09857365 · $19.3800
Shortage status: no shortage or discontinuation reported (checked October 6, 2026); reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=09857359
Shortage record checked October 6, 2026
Cefzil · DIN 02163675 · 125 mg/5 mL · Oral suspension-75mL Pk
Listed, not a benefit; Health Canada lists this DIN as Cancelled post market since 2018-01-22 — choose a marketed DIN from the same-category list.Discontinued January 22, 2018 · checked October 5, 2026
StatusListed, not a benefit; Health Canada lists this DIN as Cancelled post market since 2018-01-22 — choose a marketed DIN from the same-category list.
Write on scriptnot a benefit; no Exceptional Access criteria on record (an EAP request with clinical rationale is still possible); see alternatives; Health Canada lists this DIN as Cancelled post market since 2018-01-22 — choose a marketed DIN from the same-category list.
Patient paysNot paid by ODB 65 and over; see alternatives
1 brand, same coverage
Cefzil · DIN 02163675
Manufacturer: Bristol Myers Squibb Canada Inc; listing date 1996-12-19
Health Canada: Cancelled post market since 2018-01-22 · brand CEFZIL POWDER FOR ORAL SUSPENSION-125MG/5ML · ATC J01DC10 CEFPROZIL · form Powder for suspension · route Oral · ingredients CEFPROZIL 125 MG/5ML · company Bristol-myers squibb canada · schedule Prescription
DIN 02163675: Cefzil
Raw flags: notABenefit=Y, sec3=Y
Item: 081228083; group id 40; item number 0083; lccId None; manufacturer id BQU
Source form: Oral Susp-75mL Pk; strength: 125mg/5mL
Recorded listing: Listed, not a benefit; ODB pays only for the benefit products in this interchangeable category
Source prices (unrounded): not recorded; ministry not recorded
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02163675
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=19227Interchangeable products
Auro-Cefprozil · DIN 02347261 · $7.2750
Ran-Cefprozil · DIN 02329204 · $7.2750
Shortage status: discontinued (December 29, 2017, reported by BRISTOL-MYERS SQUIBB CANADA); reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02163675
Shortage record checked October 6, 2026
Health Canada lists this DIN as Cancelled post market since January 22, 2018 — choose a marketed DIN from the same-category list.
Cefzil · DIN 02163683 · 250 mg/5 mL · Oral suspension-75mL Pk
Listed, not a benefit; Health Canada lists this DIN as Cancelled post market since 2017-09-14 — choose a marketed DIN from the same-category list.Discontinued September 14, 2017 · checked October 5, 2026
StatusListed, not a benefit; Health Canada lists this DIN as Cancelled post market since 2017-09-14 — choose a marketed DIN from the same-category list.
Write on scriptnot a benefit; no Exceptional Access criteria on record (an EAP request with clinical rationale is still possible); see alternatives; Health Canada lists this DIN as Cancelled post market since 2017-09-14 — choose a marketed DIN from the same-category list.
Patient paysNot paid by ODB 65 and over; see alternatives
1 brand, same coverage
Cefzil · DIN 02163683
Manufacturer: Bristol Myers Squibb Canada Inc; listing date 1996-12-19
Health Canada: Cancelled post market since 2017-09-14 · brand CEFZIL POWDER FOR ORAL SUSPENSION-250 MG/ 5 ML · ATC J01DC10 CEFPROZIL · form Powder for suspension · route Oral · ingredients CEFPROZIL 250 MG/5ML · company Bristol-myers squibb canada · schedule Prescription
DIN 02163683: Cefzil
Raw flags: notABenefit=Y, sec3=Y
Item: 081228084; group id 40; item number 0084; lccId None; manufacturer id BQU
Source form: Oral Susp-75mL Pk; strength: 250mg/5mL
Recorded listing: Listed, not a benefit; ODB pays only for the benefit products in this interchangeable category
Source prices (unrounded): not recorded; ministry not recorded
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02163683
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=19226Interchangeable products
Auro-Cefprozil · DIN 02347288 · $14.5350
Ran-Cefprozil · DIN 02293579 · $14.5350
Shortage status: discontinued (August 23, 2017, reported by BRISTOL-MYERS SQUIBB CANADA); reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02163683
Shortage record checked October 6, 2026
Health Canada lists this DIN as Cancelled post market since September 14, 2017 — choose a marketed DIN from the same-category list.
Cefzil · DIN 02163659 · 250 mg · tablet
Listed, not a benefit; Health Canada lists this DIN as Cancelled post market since 2017-08-02 — choose a marketed DIN from the same-category list.Discontinued August 2, 2017 · checked October 5, 2026
StatusListed, not a benefit; Health Canada lists this DIN as Cancelled post market since 2017-08-02 — choose a marketed DIN from the same-category list.
Write on scriptnot a benefit; no Exceptional Access criteria on record (an EAP request with clinical rationale is still possible); see alternatives; Health Canada lists this DIN as Cancelled post market since 2017-08-02 — choose a marketed DIN from the same-category list.
Patient paysNot paid by ODB 65 and over; see alternatives
1 brand, same coverage
Cefzil · DIN 02163659
Manufacturer: Bristol Myers Squibb Canada Inc; listing date 1996-12-19
Health Canada: Cancelled post market since 2017-08-02 · brand CEFZIL TABLETS - 250MG · ATC J01DC10 CEFPROZIL · form Tablet · route Oral · ingredients CEFPROZIL 250 MG · company Bristol-myers squibb canada · schedule Prescription
DIN 02163659: Cefzil
Raw flags: notABenefit=Y, sec3=Y
Item: 081228085; group id 40; item number 0085; lccId None; manufacturer id BQU
Source form: Tab; strength: 250mg
Recorded listing: Listed, not a benefit; ODB pays only for the benefit products in this interchangeable category
Source prices (unrounded): not recorded; ministry not recorded
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02163659
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=19229Interchangeable products
Ran-Cefprozil · DIN 02293528 · $1.7374
Shortage status: discontinued (June 30, 2017, reported by BRISTOL-MYERS SQUIBB CANADA); reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02163659
Shortage record checked October 6, 2026
Health Canada lists this DIN as Cancelled post market since August 2, 2017 — choose a marketed DIN from the same-category list.
Cefzil · DIN 02163667 · 500 mg · tablet
Listed, not a benefit; Health Canada lists this DIN as Cancelled post market since 2017-08-22 — choose a marketed DIN from the same-category list.Discontinued August 22, 2017 · checked October 5, 2026
StatusListed, not a benefit; Health Canada lists this DIN as Cancelled post market since 2017-08-22 — choose a marketed DIN from the same-category list.
Write on scriptnot a benefit; no Exceptional Access criteria on record (an EAP request with clinical rationale is still possible); see alternatives; Health Canada lists this DIN as Cancelled post market since 2017-08-22 — choose a marketed DIN from the same-category list.
Patient paysNot paid by ODB 65 and over; see alternatives
1 brand, same coverage
Cefzil · DIN 02163667
Manufacturer: Bristol Myers Squibb Canada Inc; listing date 1996-12-19
Health Canada: Cancelled post market since 2017-08-22 · brand CEFZIL TABLETS - 500MG · ATC J01DC10 CEFPROZIL · form Tablet · route Oral · ingredients CEFPROZIL 500 MG · company Bristol-myers squibb canada · schedule Prescription
DIN 02163667: Cefzil
Raw flags: notABenefit=Y, sec3=Y
Item: 081228086; group id 40; item number 0086; lccId None; manufacturer id BQU
Source form: Tab; strength: 500mg
Recorded listing: Listed, not a benefit; ODB pays only for the benefit products in this interchangeable category
Source prices (unrounded): not recorded; ministry not recorded
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02163667
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=19228Interchangeable products
Auro-Cefprozil · DIN 02347253 · $2.0038
Ran-Cefprozil · DIN 02293536 · $2.0038
Shortage status: discontinued (July 31, 2017, reported by BRISTOL-MYERS SQUIBB CANADA); reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02163667
Shortage record checked October 6, 2026
Health Canada lists this DIN as Cancelled post market since August 22, 2017 — choose a marketed DIN from the same-category list.
Other products in the same Health Canada class (J01D, J01DC): coverage varies; not interchangeable
Cefuroxime axetil (Ceftin): general benefit, not a benefit
Cefoxitin (Mefoxin): not a benefit
Cefadroxil (Duricef): general benefit, not a benefit
Cefixime (Suprax): general benefit
Ceftriaxone (Rocephin): general benefit, not a benefit
Cephalexin (Ceporex): general benefit, not a benefit
1 more in the class list below
Other drugs in the same formulary class (08:12:28 Other Antibiotics) and how they are covered
Matched class: 08:12:28 Other Antibiotics
Drug-class inventory only. Lists recorded Ontario formulary products, not every Canadian medication; does not recommend treatment.
Public program routes: ODB 65 and over
Covered without a code on the Ontario formulary: CEFIXIME, CLINDAMYCIN PALMITATE
Some products covered without a code (check the product listing): CEFADROXIL, CEFTRIAXONE DISODIUM, CEFUROXIME AXETIL, CEPHALEXIN MONOHYDRATE, CLINDAMYCIN HCL, TOBRAMYCIN, TOBRAMYCIN SULFATE
08:12:28 Other Antibiotics
· 16 products · Listed, not a benefit (3), General benefit (9), General benefit; DIN status E (meaning unconfirmed); confirm discontinuation/availability with Health Canada (1), Off-Formulary Interchangeable, not an ODB benefit (3) · strengths: 0.25g/Vial, 1g/Vial, 2g/Vial, 10g/Vial · Inj Pd-Vial Pk
· 1 products · Limited Use, codes 677 · strengths: 500mg/Vial · Pd for Sol (Preservative-Free)
Source: formulary-ed43-front-matter.txt Part V; ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=2026-09-22; class 08:12:28
and 4 more
INDICATIONS AND CLINICAL USE
SPC-Cefprozil (cefprozil) is indicated for the treatment of the following infections caused by
susceptible strains of the designated microorganisms:
Upper Respiratory Tract
Pharyngitis / tonsillitis caused by group A ß-hemolytic (GABHS) Streptococcus pyogenes.
Substantial data establishing the efficacy of cefprozil in the subsequent prevention of rheumatic
fever are not available at present, although no case was reported during its evaluation in over 978
pediatric and 831 adult patients in controlled clinical trials.
Otitis media caused by Streptococcus pneumoniae, Haemophilus influenzae, Moraxella
(Branhamella) catarrhalis.
Acute sinusitis caused by Streptococcus pneumoniae, Haemophilus influenzae, (beta-lactamase
positive and negative strains), and Moraxella (Branhamella) catarrhalis.
Skin And Skin Structure
Uncomplicated skin and skin-structure infections caused by Staphylococcus aureus
(including penicillinase-producing strains) and Streptococcus pyogenes.
Urinary Tract
Uncomplicated urinary tract infections (including acute cystitis) caused by Escherichia coli,
Pr
SPC-Cefprozil – Product Monograph …
https://pdf.hres.ca/dpd_pm/00080833.PDF
PM date: JUN 18, 2025
Source product: SPC-CEFPROZIL; DIN 02293528; fetched 2026-09-10
Product monograph posted by Health Canada; excerpt for lookup only.
Availability
Cefzil · DIN 02163675
Shortage status: discontinued (2017-12-29, reported by BRISTOL-MYERS SQUIBB CANADA); reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02163675
Cefzil · DIN 02163683
Shortage status: discontinued (2017-08-23, reported by BRISTOL-MYERS SQUIBB CANADA); reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02163683
Cefzil · DIN 02163659
Shortage status: discontinued (2017-06-30, reported by BRISTOL-MYERS SQUIBB CANADA); reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02163659
Cefzil · DIN 02163667
Shortage status: discontinued (2017-07-31, reported by BRISTOL-MYERS SQUIBB CANADA); reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02163667
Public program routes (Ontario context; residency, health-card/OHIP requirements and enrolment must be confirmed from the quoted rules):
ODB 65 and over (seniors path)
Eligibility: You may qualify for the Ontario Drug Benefit (ODB) program when you turn 65 years old. (ontario.ca, August 18, 2026 ↗)
Eligibility: The Ontario Drug Benefit program is for Ontario residents only and prescriptions must be filled in an Ontario pharmacy to be covered. (ontario.ca, August 18, 2026 ↗)
Eligibility: Individual annual net income threshold
Program year August 1, 2026 to July 31, 2027: $25,480
This applies to a senior who:
does not have a spouse
has a married spouse with whom they no longer live in a conjugal relationship
has a spouse living in a long-term care home or community home for opportunity (ontario.ca, July 2, 2026 ↗)
Eligibility: Combined annual net income requirement
Program year August 1, 2026 to July 31, 2027: $42,290
This applies to a senior who has a spouse, other than a spouse described. (ontario.ca, July 2, 2026 ↗)
Eligibility: See the first-year deductible table. (ontario.ca, August 18, 2026 ↗)
What it pays / costs: the first $100 of total prescription costs each program year (August 1 to July 31 the following year) (ontario.ca, August 18, 2026 ↗)
What it pays / costs: up to $6.11 for each prescription filled or refilled (after paying the deductible) (ontario.ca, August 18, 2026 ↗)
What it pays / costs: Seniors enrolled in the Seniors Co-Payment Program have no annual deductible and a reduced co-payment of up to $2. (ontario.ca, August 18, 2026 ↗)
Enrolment: "We will send you a letter about 3 months before your 65th birthday to let you know you will automatically join the Ontario Drug Benefit program on the first day of the month after you turn 65 years old." (ontario.ca, August 18, 2026 ↗)
Enrolment: "To enroll in the Seniors Co-Payment Program, a senior must submit an application to that program and qualify under certain income eligibility thresholds." (ontario.ca, August 18, 2026 ↗)
First year on ODB? The deductible depends on birth month
For your first year of Ontario Drug Benefit program eligibility, depending on the month you turn 65, the deductible may be lower than $100.
That’s because the amount of the deductible is based on the number of months between your official start date (the first day of the month after you turn 65) and July 31 (the last day of the Ontario Drug Benefit program year).
For example, if you turned 65 on April 15, your official start date would be May 1. Counting from May 1 to July 31 your deductible for the first year would be $25.
Use this chart below to see what the deductible will be in your first year:
For Cefzil: no applicable EAP criteria are held and no ODB benefit is established. These policies do not establish coverage.
For rare, immediately life-, limb- or organ-threatening circumstances, the Compassionate Review Policy may consider an unfunded drug or indication, subject to its criteria and without bypassing the drug review process. Compassionate Review Policy
Compassionate Review Policy: source quote
Where there are rare clinical circumstances in immediately life, limb, or organ-threatening conditions, the Executive Officer will also consider requests for drugs or indications in situations where there has not been a decision by the Executive Officer to provide funding of the drug or indication as part of the Ontario Drug Benefit program (and the EAP), and the drug or indication requested would not circumvent the established review process for new drugs or indications as part of the drug submission process for listing within the Ontario Drug Benefit program. Requests must meet the criteria for the Compassionate Review Policy.
For cancer drugs, Case-by-Case Review considers rare, immediately life-threatening circumstances when no satisfactory funded treatment exists; its criteria and application process apply. Case-by-Case Review (cancer drugs)
Case-by-Case Review (cancer drugs): source quote
Note: Requests for cancer drugs are considered under the Case-by-Case Review Program (CBCRP) which is administered by Ontario Health (Cancer Care Ontario) on behalf of the Ministry of Health. The CBCRP considers funding requests for drugs (both oral therapies and injectable drugs) for the treatment of cancer in patients who have a rare clinical circumstance that is immediately life-threatening (death is likely within a matter of months) and who require treatment with an unfunded drug, because there is no other satisfactory and funded treatment. Please refer to the Ontario Health website for information on the application process, FAQs, eligibility criteria and program policies.